BioSpace News Archive

The Children’s Tumor Foundation and the Global Coalition for Adaptive Research – The Children’s Tumor Foundation and Global Coalition for Adaptive Research, announced their alliance to accelerate the development of treatments for patients with NF – a group of rare and often debilitating diseases with high unmet medical need.

Inovedis GmbH, a medical technology start-up dedicated to offering innovative solutions that contribute both to optimized patient care as well as minimizing the complexity of surgical interventions, announced the successful close of a Series A funding round totaling $4 million.

ChromaCode, Inc. is proud to announce the publication of the first peer-reviewed demonstration of non-small-cell lung cancer (NSCLC) variant detection using ChromaCode’s groundbreaking High Definition PCR (HDPCR™) technology.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to seven new employees with a grant date of October 2, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2024 on Thursday, October 26, 2023, after the New York Stock Exchange closes.

ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today announced the appointment of Nick Pullen, Ph.D., as Chief Scientific Officer.

Biohaven Ltd. today announced the closing of its underwritten public offering of 11,761,363 of its common shares, which includes the full exercise of the underwriters’ option to purchase 1,534,090 additional common shares, at a public offering price of $22.00 per share.

AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its third quarter 2023 financial results and fourth quarter 2023 outlook on Thursday, November 2, 2023, at 5:00 p.m. Eastern Time.

Athira Pharma, Inc. (NASDAQ: ATHA) presented new preclinical data supporting the potential benefit of ATH-1105 for the treatment of amyotrophic lateral sclerosis (ALS) at the 22nd Annual Northeast ALS Consortium (NEALS) Meeting, taking place October 4-6, 2023, virtually and in-person in Clearwater, Florida.

Celltrion USA has signed a contract with Ventegra ®, a major U.S. Medical Benefits Manager (MBM) who administers pharmacy benefits through its Pharmacy Services Administration (PSA) model that has been effectively displacing traditional PBM’s.